Search
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … [L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker.
Nicergoline
go.drugbank.com/drugs/DB00699ApprovedAn ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Categories: Heterocyclic Compounds with 4 or More RingsSalsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. … A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour.
Synonyms: o-Salicylsalicylic acid, O-SalicylcylsalicylsäureElivaldogene autotemcel
go.drugbank.com/drugs/DB16746ApprovedElivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells. … Without sufficient levels of functional ALDP, VLCFAs accumulate in the body leading to inflammation and destruction of myelin, which is an insulating layer and essential component of nerves.
International brands: Lenti-DGlofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigational], [vincristine], [prednisone])[L45763] - despite this, as many as 40% of patients will experience relapsed or refractory disease. … This approval is based on the positive results obtained from the phase I/II NP30179 study, where 35.2% of study participants achieved a complete response.[L47451]
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalOn October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas. … Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery.
Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexOlaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalOlaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016. … Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linkerDP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment … of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnAs a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting … Tropisetron is an indole derivative with antiemetic activity.